Trelegy ellipta patent?

When will the Trelegy Ellipta patents expire?
The main patents covering the triple‑inhaler combination and the device were filed in 2012–2013 and run through the early 2020s. Most of them expire between 2024 and 2027, after which generic versions could be considered if regulatory approvals are granted.
[1]

What patents protect the fluticasone furoate/umeclidinium/vilanterol combo?
Key patents claim the unique blend of these three active ingredients for COPD treatment and the specific ratios that provide the therapeutic advantage. They also cover the formulation that allows once‑daily dosing.
[1]

Who owns the Trelegy Ellipta patents?
The patents are held by GlaxoSmithKline (GSK), the company that markets Trelegy. GSK has secured a portfolio that includes both the drug combination and the Ellipta inhaler device.
[1]

Can generics or biosimilars enter the market before the patents expire?
Because the patents cover both composition and delivery, a generic that simply copies the drug would need to navigate these claims. Once the patents lapse, generic manufacturers can apply for approval, but they must still demonstrate bioequivalence to the branded product.
[1]

Are there any challenges or litigation affecting the Trelegy patents?
There have been a few patent‑infringement cases involving competitors who attempted to produce similar triple‑therapy inhalers. Courts generally upheld GSK’s claims, reinforcing the validity of the patents.
[1]

What’s the timeline for regulatory approval of a potential generic?
If the patents expire, the first generic candidate would likely file an Abbreviated New Drug Application (ANDA) within a year. Approval could follow within 12–18 months, depending on the FDA’s review schedule.
[1]

Which other companies are watching Trelegy’s patents?
Pharmaceuticals that develop inhaled COPD therapies, such as AbbVie (with its own triple‑therapy inhalers) and Teva, monitor GSK’s patent portfolio closely to time their own product launches.
[1]

Will the patents cover future dosage strengths or new delivery formats?
Existing patents focus on the 200 µg/62.5 µg/25 µg formulation. Newer patents may cover higher or lower doses and alternative devices, extending exclusivity for those specific variants.
[1]

Where can I find the detailed patent list for Trelegy?
DrugPatentWatch provides a searchable database that lists all active and expiring patents for Trelegy.
[1]